Wound Care Innovations, LLC, a subsidiary of Wound Management Technologies, Inc., (OTC Bulletin Board: WNDM - News), is excited about expanding upon the announcement that was made on Tuesday regarding the publication of (2) independent case reports utilizing their advanced wound care collagen product, CellerateRx®, in the August edition of Advances in Skin and Wound Care. The case presentations were on recalcitrant diabetic wounds. The article will be available in its entirety for viewing on the company website, www.celleraterx.com in two weeks.

Wound Care Innovations, LLC, a subsidiary of Wound Management Technologies, Inc., (OTC Bulletin Board: WNDM - News), announced today the publication of (2) independent case reports utilizing their advanced wound care collagen product, CellerateRx®, in the August edition of Advances in Skin and Wound Care. The case presentations were on recalcitrant diabetic wounds. "Many factors have been implicated in the problematic nature of diabetic wounds to the lower extremities," states Cathy Bradshaw, President of Wound Care Innovations.

Wound Care Innovations, LLC, a subsidiary of Wound Management Technologies, Inc., (OTC Bulletin Board: WNDM - News), announced today that it has entered into a confidentiality agreement with a company to register and distribute their advanced wound care collagen products, CellerateRx®, in Taiwan. "We have had a tremendous response and inquiries from the international community about CellerateRx®," states Cathy Bradshaw, President of Wound Care Innovations.

Wound Care Innovations, LLC, a subsidiary of Wound Management Technologies, Inc., (OTC Bulletin Board: WNDM - News), announced today an evidence based study with a NE podiatric clinic evaluating the clinical performance of their advanced wound care collagen product, CellerateRx®, on diabetic venous ulcers. "According to data released by the Centers for Disease Control and Prevention, diabetes now affects nearly 24 million people in the United States alone," states Cathy Bradshaw, President of Wound Care Innovations.

Wound Management Technologies, Inc., (OTC Bulletin Board: WNDM - News), announced today the filing of a new 510K on a new wound management product utilizing their patented hydrolyzed collagen technology.

Wound Management Technologies, Inc., (OTC Bulletin Board: WNDM - News), has announced the signing of a commission based, sales agreement for its wound care product, CellerateRx®, with EWA Government Systems, Inc. (EWA GSI). This agreement follows discussions and demonstrations, and validates that CellerateRx is destined to play a vital role in international wound management. CellerateRx patented collagen fragments (CRX) are a fraction of the size of native collagen molecules found in other products, and provide the benefits of collagen to the body immediately.

MB Software Corporation (OTC Bulletin Board: MBSB - News) announced today that Company's new symbol will be (OTC Bulletin Board: WNDM - News). This change was made by the OTCBB to reflect the Company's new name, Wound Management Technologies, Inc. The company is also announcing that the Company's Vice President of Corporate Development, Cathy Bradshaw, will move to the position of President of Wound Care Innovations, LLC. The firm is also currently in the process of searching for an Advisory Board and Board of Directors as it develops its to market strategy for Cellerate Rx.